贝利尤单抗治疗系统性红斑狼疮的真实世界疗效:中国单中心前瞻性队列研究
该前瞻性队列研究纳入123例中国SLE患者,其中新诊断33例、复发32例、难治58例,中位随访12个月(范围3-18个月)。贝利尤单抗联合标准治疗在各随访点SRI-4应答率为55.77%至63.64%,新诊断组SRI-4应答率最高且血清学与SLEDAI-2K改善最显著。
要点
- 贝利尤单抗联合标准治疗在3至18个月随访中SRI-4应答率在55.77%至63.64%之间。
- 新诊断组SRI-4应答率最高,血清学参数和SLEDAI-2K改善最显著。
- 与单用标准治疗的新诊断患者相比,联用贝利尤单抗者累计泼尼松摄入量显著降低。
核心结论
- 数据支持贝利尤单抗在中国SLE患者真实世界环境中的疗效。
- 研究提供新证据表明新诊断SLE患者在接受贝利尤单抗治疗期间SRI-4应答率显著。
研究设计与样本
- 前瞻性队列研究,连续纳入2021年7月至2022年12月接受贝利尤单抗联合标准治疗的中国SLE患者。
- 根据基线特征分为新诊断组(开始贝利尤单抗4周内新诊断SLE)、复发组(经历严重复发)和难治组(糖皮质激素减量不满意和/或疾病活动控制不佳)。
- 共123例SLE患者纳入分析,中位随访12个月(范围3-18个月);新诊断33例,复发32例,难治58例。
- 另纳入单用标准治疗的新诊断患者和健康对照。
主要发现
- SRI-4应答率:3个月55.77%,6个月56.63%,9个月63.24%,12个月63.64%,18个月57.14%,耐受良好。
- 血清学参数(抗dsDNA抗体和C3/C4)、SLEDAI-2K及每日泼尼松摄入量在总体和各组中均改善。
- 三组中新诊断组SRI-4应答率最高,血清学参数和SLEDAI-2K改善最显著。
- 与单用标准治疗的新诊断患者相比,联用贝利尤单抗的新诊断患者累计泼尼松摄入量显著降低。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective of this study was to explore the efficacy and safety of belimumab among Chinese patients with SLE in a real-world setting. METHODS: A prospective cohort study was performed, and SLE patients taking belimumab on a background of standard-of-care (SoC) treatment were consecutively enrolled from July 2021 to December 2022. Based on baseline characteristics, the patients were divided into three groups: the newly diagnosed group, the relapsed group and the refractory group. Patients in the newly diagnosed group were newly diagnosed with SLE within 4 weeks of starting belimumab. Patients in the relapse group had experienced a severe flare. Refractory patients were patients with unsatisfactory GC taper and/or disease activity control. Clinical data were collected, and disease assessments were conducted regularly. Newly diagnosed patients with SoC alone and healthy controls (HCs) were also enrolled. RESULTS: A total of 123 SLE patients were included in the analysis, with a median follow-up period of 12 months (range 3-18 months). Thirty-three out of 123 patients were newly diagnosed, 32 had relapsed disease, and 58 had refractory disease. The SLE Responder Index 4 (SRI-4) response was achieved with good tolerance by 55.77% of patients at 3 months, 56.63% at 6 months, 63.24% at 9 months, 63.64% at 12 months and 57.14% at 18 months. Serological parameters (anti-dsDNA and C3/C4), SLEDAI-2K and daily prednisone intake were improved overall and in each group. Of the three groups, the newly diagnosed group had the highest SRI-4 rate as well as the greatest improvement in serological parameters and SLEDAI-2K. Compared with newly diagnosed patients with SoC alone, the cumulative prednisone intake of newly diagnosed patients taking belimumab was significantly decreased. CONCLUSION: Our data supported the efficacy of belimumab in Chinese SLE patients in a real-life setting. Our study also provided new evidence indicating remarkable achievement of the SRI-4 response during belimumab therapy in newly diagnosed SLE patients.
引用
- Zhao Y, Qi F, Bai J, et al. Real-world efficacy of belimumab in systemic lupus erythematosus: a prospective cohort from a single centre in China. Rheumatology (Oxford). 2025. PMID: 38011668. doi:10.1093/rheumatology/kead629
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。